Dx & Vx Co., Ltd. (KOSDAQ:180400)
South Korea · Delayed Price · Currency is KRW 1,982.00
-16.00 (-0.80%)
At close: Oct 23, 2026
Dx & Vx Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 26,224 | 29,357 | 33,947 | 41,244 | 32,184 | 7,470 |
Revenue Growth | -15.72% | -13.52% | -17.69% | 28.15% | 330.83% | -2.94% |
Gross Profit Gross Profit Growth | 1,677 | 3,320 | 5,139 | 7,575 | 10,030 | 635.68 |
Operating Income Operating Income Growth | -21,023 | -24,317 | -21,597 | -15,449 | 2,634 | -3,713 |
Net Income Net Income Growth | -25,219 | -29,039 | -47,034 | -27,482 | -779.65 | -7,269 |
Earnings Per Share EPS Growth | -340.37 | -586.78 | -1309.06 | -929.21 | -27.17 | -297.72 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Healthcare Healthcare Growth | 22,223 | 26,260 | 31,693 | 36,067 | 20,205 |
Medical Diagnosis Medical Diagnosis Growth | 3,766 | 3,009 | 2,167 | 5,131 | 11,980 |
New Drug New Drug Growth | 235.05 | 87.6 | 86.29 | 45.6 | - |
Total Total Growth | 26,224 | 29,357 | 33,947 | 41,244 | 32,184 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 49,941 | 105,018 | 11,214 | 12,572 | 26,846 | 2,614 |
Total Debt Total Debt Growth | 14,642 | 47,989 | 42,784 | 39,822 | 35,456 | 5,236 |
Net Cash (Debt) Net Cash Growth | 35,299 | 57,030 | -31,571 | -27,250 | -8,610 | -2,622 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 476.40 | 1152.37 | -878.68 | -921.35 | -300.09 | -107.38 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -20,682 | -18,855 | -20,026 | -12,061 | 865.55 | -2,760 |
Capital Expenditures CapEx Growth | -1,473 | -998.43 | -637.87 | -760.18 | -1,350 | -941.61 |
Free Cash Flow Free Cash Flow Growth | -22,155 | -19,853 | -20,664 | -12,822 | -484.03 | -3,701 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 6.39% | 11.31% | 15.14% | 18.37% | 31.16% | 8.51% |
Operating Margin | -80.17% | -82.84% | -63.62% | -37.46% | 8.19% | -49.70% |
Pretax Margin | -104.20% | -108.96% | -164.75% | -73.64% | -8.87% | -92.08% |
Profit Margin | -96.17% | -98.92% | -138.55% | -66.63% | -2.42% | -97.31% |
FCF Margin | -84.48% | -67.63% | -60.87% | -31.09% | -1.50% | -49.55% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 7.44 | 5.26 | 2.70 | 4.33 | 6.90 | 29.73 |